| Description | L-Clausenamide is an alkaloid extracted from the leaves of the yellow bark (Clausena lansium (Lour) skeels) and can be used to improve cognitive function. L-Clausenamide inhibits beta-amyloid (Aβ) toxicity and prevents the formation of neurofibrillary tangles by inhibiting tau phosphorylation. L-Clausenamide has neuroprotective activity and can be used to modulate stimuli triggered by Aβ25-35. L-Clausenamide can be used to study neurological disorders like Alzheimer's disease. |
| In vitro | Reversing the overload in [Ca2+]i level stimulated by Aβ25-35 and reducing Aβ-mediated cell apoptosis in PC12 cells, (-)Clausenamide (10 and 100 μM) demonstrates its protective effects[3].In Aβ25-35-treated PC12 cells, (-)Clausenamide (10 and 100 μM) inhibits the phosphorylation of p38 MAPK and down-regulates the expression of P53 and cleaved Caspase-3, as well as the ratio of Bax/Bcl-2[3]. |
| Synonyms | (-)-Clausenamide |
| molecular weight | 297.35 |
| Molecular formula | C18H19NO3 |
| CAS | 201529-58-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (168.15 mM) |
| References | 1. Chu S, Liu S, Duan W, et al. The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect. Pharmacol Ther. 2016;162:179-187. 2. Chu SF, Zhang JT. Recent advances in the study of (-)clausenamide: chemistry, biological activities and mechanism of action. Acta Pharm Sin B. 2014;4(6):417-423. 3. Hu JF, et al. Protective effect of (-)clausenamide against Abeta-induced neurotoxicity in differentiated PC12 cells. Neurosci Lett. 2010 Oct 8;483(1):78-82. |